BigHat Biosciences CSO Peyton Greenside and CEO Mark DePristo

'Not in to­day's mar­ket': As Am­gen, Bris­tol My­ers back an­ti­body start­up BigHat, bear mar­ket keeps IPO win­dow shut tight

A pri­vate an­ti­body start­up is pulling in some new cash to con­tin­ue ad­vanc­ing its dis­cov­ery-stage pro­grams, re­cruit­ing some big back­ers in the process. But in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.